Imed19-Privat

Vienna 10 trials 1 recruiting

10 Registered trials

1 Currently recruiting

Organisation

Imed19-Privat

Location

Vienna, Austria

Identifier

ORG-100045343

Address

Chimanistrasse 1, Doebling, 1190, Austria

Departments

2000
Imed 19
Imed19 Privat
Imed19-privat
Internal Medicine
N/A
N/A- private practice
NA

Clinical trials at this site (10)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Prevention of heart disease in heart-healthy patients with diabetes based on a special parameter (NT-proBNP) Pending

2024-519051-28-01 Diabetes mellitus Type 2 6
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended

2023-509709-63-00 Chronic Kidney Disease and Albuminuria 4 2024-07-30
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29